Pirera, E.; Di Raimondo, D.; D’Anna, L.; Tuttolomondo, A.
Efficacy of SGLT2 Inhibitors, GLP-1 Receptor Agonists, DPP-4 Inhibitors, and Sulfonylureas on Moderate-to-Severe COPD Exacerbations Among Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. Pharmaceuticals 2025, 18, 1337.
https://doi.org/10.3390/ph18091337
AMA Style
Pirera E, Di Raimondo D, D’Anna L, Tuttolomondo A.
Efficacy of SGLT2 Inhibitors, GLP-1 Receptor Agonists, DPP-4 Inhibitors, and Sulfonylureas on Moderate-to-Severe COPD Exacerbations Among Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. Pharmaceuticals. 2025; 18(9):1337.
https://doi.org/10.3390/ph18091337
Chicago/Turabian Style
Pirera, Edoardo, Domenico Di Raimondo, Lucio D’Anna, and Antonino Tuttolomondo.
2025. "Efficacy of SGLT2 Inhibitors, GLP-1 Receptor Agonists, DPP-4 Inhibitors, and Sulfonylureas on Moderate-to-Severe COPD Exacerbations Among Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis" Pharmaceuticals 18, no. 9: 1337.
https://doi.org/10.3390/ph18091337
APA Style
Pirera, E., Di Raimondo, D., D’Anna, L., & Tuttolomondo, A.
(2025). Efficacy of SGLT2 Inhibitors, GLP-1 Receptor Agonists, DPP-4 Inhibitors, and Sulfonylureas on Moderate-to-Severe COPD Exacerbations Among Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. Pharmaceuticals, 18(9), 1337.
https://doi.org/10.3390/ph18091337